Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eperisone + aceclofenac is a fixed-dose combination of two pharmaceutical agents used primarily for the management of pain associated with muscle spasms, such as those occurring in acute low back pain, neck pain, musculoskeletal injuries (sprains and strains), myofascial pain syndrome, and fibromyalgia[1][2][4][7]. Eperisone is a centrally acting muscle relaxant that works by relaxing skeletal muscles through action on the brain and spinal cord centers. It also relaxes vascular smooth muscles and improves blood circulation[1][2]. Aceclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase enzymes (COX), particularly COX‑2, thereby reducing prostaglandin synthesis responsible for inflammation and pain[6]. The combination provides both analgesic (pain relief) and antispasmodic effects to improve mobility in patients with painful muscle conditions. This medication is available as oral tablets for adult use only.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on eperisone + aceclofenac.